众生药业上涨8.36%，报24.88元/股

Core Viewpoint - On August 19, Zhongsheng Pharmaceutical experienced an intraday increase of 8.36%, reaching a stock price of 24.88 yuan per share, with a trading volume of 1.238 billion yuan and a turnover rate of 6.81%, resulting in a total market capitalization of 21.146 billion yuan [1] Company Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan City, Guangdong Province, and is a top 100 pharmaceutical company focusing on ophthalmology, cardiovascular, respiratory, and digestive treatment areas [1] - The company operates ten subsidiaries and four production bases, with major products including Compound Thrombus Capsule, Brain Thrombus Capsule, and Zhongsheng Pill [1] - Zhongsheng Pharmaceutical has 16 chemical drug products that have passed the consistency evaluation of generic drugs, with five products selected in the national centralized procurement [1] - The company has established a multi-level R&D system based on characteristic traditional Chinese medicine, high-end generic drugs, and innovative drugs, with the innovative drug Liratevir Tablets approved for market on March 23, 2023 [1] Financial Performance - For the period from January to March 2025, Zhongsheng Pharmaceutical achieved an operating income of 634 million yuan, a year-on-year decrease of 1.07%, while the net profit attributable to shareholders was 82.6118 million yuan, reflecting a year-on-year increase of 61.06% [1] - As of March 31, the number of shareholders of Zhongsheng Pharmaceutical was 91,100, with an average of 8,359 circulating shares per person [1]